Nanovibronix (NAOV) Stock Price, News & Analysis

Company Overview

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

Key Stats

• Today's Range: $5.70 to $7.38
• 50-Day Range: $6.91 to $12.00
• 52-Week Range: $5.70 to $162.50
• Volume: 92,327 shs
• Average Volume: 93,324 shs
• Market Capitalization: $1.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Nanovibronix Stock Analysis - MarketRank™

Nanovibronix scored higher than 8% of companies evaluated by MarketBeat, and ranked 926th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Nanovibronix.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nanovibronix is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nanovibronix is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nanovibronix has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.41% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently decreased by 72.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanovibronix does not currently pay a dividend.

Dividend Growth

Nanovibronix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.41% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently decreased by 72.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.02

News Sentiment

Nanovibronix has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Nanovibronix this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanovibronix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Nanovibronix is held by insiders.

Percentage Held by Institutions

Only 16.39% of the stock of Nanovibronix is held by institutions.

NAOV Stock Analysis - Frequently Asked Questions

How have NAOV shares performed this year?

Nanovibronix's stock was trading at $64.90 at the start of the year. Since then, NAOV stock has decreased by 89.4% and is now trading at $6.91.

How were Nanovibronix's earnings last quarter?

Nanovibronix, Inc. (NASDAQ:NAOV) posted its earnings results on Tuesday, May, 20th. The company reported ($39.80) earnings per share (EPS) for the quarter. The business had revenue of $1.02 million for the quarter. Nanovibronix had a negative net margin of 210.82% and a negative trailing twelve-month return on equity of 54.73%.

When did Nanovibronix's stock split?

Nanovibronix's stock reverse split before market open on Tuesday, August 12th 2025.The 1-10 reverse split was announced on Friday, August 8th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Nanovibronix?

Shares of NAOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nanovibronix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanovibronix investors own include Exela Technologies (XELA), Assertio (ASRT), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO), Senseonics (SENS) and SNDL (SNDL).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NAOV
• CIK: 1326706
• Web: www.nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($13.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.70 million
• Net Margins: -210.82%
• Pretax Margin: -209.80%
• Return on Equity: -54.73%
• Return on Assets: -38.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $2.56 million
• Price / Sales: 0.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.38 per share
• Price / Book: 0.38

Miscellaneous

• Outstanding Shares: 260,000
• Free Float: 242,000
• Market Cap: $1.80 million
• Optionable: Not Optionable
• Beta: 1.83